Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Adult Anaplastic AstrocytomaAdult Diffuse Astrocytoma6 moreThis phase II trial is studying how well sunitinib works in treating patients with recurrent malignant gliomas. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma...
Anaplastic AstrocytomaGlioblastomaWe are asked patients to take part in this study because they had recurrent (returned) (1st or 2nd) anaplastic astrocytoma (AA) or glioblastoma multiforme (GBM). The purposes of this study are: To see if Sutent has any change on the patient and their cancer. To see if Sutent will slow or stop the growth of their tumor. To measure the safety of Sutent. Sutent is Food and Drug Administration (FDA) approved to treat patients with a gastrointestinal stromal tumor after the disease worsened while taking another medicine called imatinib mesylate or when imatinib mesylate cannot be taken. Sutent is also FDA approved to treat patients with advanced renal cell carcinoma. At this time, it is not known whether Sutent will improve symptoms, or help patients with this disease live longer.
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
GlioblastomaAstrocytoma3 moreThe purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With...
GlioblastomaAnaplastic Astrocytoma2 moreThis is a multicenter, open-label, ascending-dose trial of the safety and tolerability of increasing doses of Toca 511, a Retroviral Replicating Vector (RRV), administered to patients with recurrent high grade glioma (rHGG) who have undergone surgery followed by adjuvant radiation therapy and chemotherapy. Patients will receive Toca 511 either via stereotactic, transcranial injection into their tumor or as an intravenous injection given daily for 3 & 5 days, depending on cohort. Approximately 3-4 weeks following injection of the RRV, treatment with Toca FC, an antifungal agent, will commence and will be repeated approximately every 6 weeks until study completion. After completion of this study, all patients will be eligible for enrollment and encouraged to enter a long-term continuation protocol that enables additional Toca FC treatment cycles to be given, as well as permits the collection of long-term safety and survival data.
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex...
Tuberous SclerosisSubependymal Giant Cell AstrocytomaThe purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The hypothesis is that the drug will cause the tumor size to decrease, and may have beneficial activity separate from effects on tumors in patients.
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide...
Adult Anaplastic AstrocytomaAdult Anaplastic Oligodendroglioma3 moreThis phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide. VEGF Trap may stop the growth of malignant or anaplastic gliomas by blocking blood flow to the tumor.
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Childhood Burkitt LymphomaChildhood Central Nervous System Germ Cell Tumor24 moreThis phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic AstrocytomaAdult Anaplastic Oligodendroglioma3 moreThis phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous...
Childhood Central Nervous System Germ Cell TumorChildhood Extragonadal Germ Cell Tumor24 moreThis phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus Tumor24 moreThis phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.